miR-193b Regulates Mcl-1 in Melanoma - PubMed (original) (raw)
miR-193b Regulates Mcl-1 in Melanoma
Jiamin Chen et al. Am J Pathol. 2011 Nov.
Abstract
MicroRNAs play important roles in gene regulation, and their expression is frequently dysregulated in cancer cells. In a previous study, we reported that miR-193b represses cell proliferation and regulates cyclin D1 in melanoma cells, suggesting that miR-193b could act as a tumor suppressor. Herein, we demonstrate that miR-193b also down-regulates myeloid cell leukemia sequence 1 (Mcl-1) in melanoma cells. MicroRNA microarray profiling revealed that miR-193b is expressed at a significantly lower level in malignant melanoma than in benign nevi. Consistent with this, Mcl-1 is detected at a higher level in malignant melanoma than in benign nevi. In a survey of melanoma samples, the level of Mcl-1 is inversely correlated with the level of miR-193b. Overexpression of miR-193b in melanoma cells represses Mcl-1 expression. Previous studies showed that Mcl-1 knockdown cells are hypersensitive to ABT-737, a small-molecule inhibitor of Bcl-2, Bcl-X(L), and Bcl-w. Similarly, overexpression of miR-193b restores ABT-737 sensitivity to ABT-737-resistant cells. Furthermore, the effect of miR-193b on the expression of Mcl-1 seems to be mediated by direct interaction between miR-193b and seed and seedless pairing sequences in the 3' untranslated region of Mcl-1 mRNA. Thus, this study provides evidence that miR-193b directly regulates Mcl-1 and that down-regulation of miR-193b in vivo could be an early event in melanoma progression.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
Figures
Figure 1
Expression of miR-193b and Mcl-1 in melanoma tissue samples. A: miR-193b expression was measured by Agilent miRNA microarray. The black line indicates the mean value for each group. B: Mcl-1 staining was scored in metastatic melanomas, primary melanomas, and benign nevi. Data shown are mean ± SEM. C: Pearson correlation analysis was performed to determine the relationship between miR-193b expression and Mcl-1 expression. The results show an inverse correlation (r = −0.7 and P < 0.001). *P < 0.0001 was calculated using the independent samples _t_-test.
Figure 2
miR-193b down-regulates Mcl-1 and sensitizes melanoma cells to ABT-737. A: Western blot analysis of Mcl-1 and cleaved PARP expression in Malme-3M, MeWo, SK-MEL-2, and SK-MEL-28 cells transfected with miR-193b or negative control. Cells were transfected with 5 nmol/L miRNA precursor (miR-193b or negative control) and were harvested 72 hours after transfection. B: Western blot analysis of cleaved PARP and Mcl-1 in Malme-3M cells transfected with miR-193b or negative control, as indicated, incubated for 56 hours, and treated with 10 mmol/L ABT-737, as indicated. Cells were harvested 72 hours after transfection. C: Western blot analysis of MeWo and SK-MEL-28 cells, as indicated. The procedure was performed as described in B. D: One microgram of Mcl-1 plasmid (pMcl-1) was cotransfected with 5 nmol/L miRNA precursors, as indicated, and treated with 10 nmol/L ABT-737 as described in B. Gamma tubulin was used as the loading control. Representative data from one of three independent experiments are shown.
Figure 3
miR-193b directly targets the 3′ UTR of Mcl-1. A: miR-193b and its predicted seed binding site in the 3′ UTR of Mcl-1 (top). The underlined 8-nucleotide sequence indicates the miR-193b seed region. Relative luciferase activity is shown for reporter constructs containing 3′ UTR or 3′ UTR M (with deleted seed pairing region) (bottom) in cells transfected with miR-193b or negative control. B: As in A, except reporter constructs carried the indicated fragment of the Mcl-1 3′ UTR (top). Four MREs predicted by RNA22 in the 3′ UTR of Mcl-1 (middle). C: As in A, except reporter constructs carried UTR1 M1 or UTR1 M2 (top). UTR1 M1 contains two point mutations, as indicated in bold italic. UTR1 M2 contains no seed binding region. Renilla luciferase activity was measured 24 hours after transfection using the Dual-Glo luciferase assay system (Promega). Data were normalized to firefly luciferase. Data shown are the mean ± SEM of three replicates and are representative of three independent experiments. *P < 0 0.05 and **P < 0.001 were calculated using the paired samples _t_-test.
Similar articles
- MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma.
Chen J, Feilotter HE, Paré GC, Zhang X, Pemberton JG, Garady C, Lai D, Yang X, Tron VA. Chen J, et al. Am J Pathol. 2010 May;176(5):2520-9. doi: 10.2353/ajpath.2010.091061. Epub 2010 Mar 19. Am J Pathol. 2010. PMID: 20304954 Free PMC article. - Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.
Hauck P, Chao BH, Litz J, Krystal GW. Hauck P, et al. Mol Cancer Ther. 2009 Apr;8(4):883-92. doi: 10.1158/1535-7163.MCT-08-1118. Mol Cancer Ther. 2009. PMID: 19372561 - 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.
Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA, Fesik SW, Shen Y. Lin X, et al. Oncogene. 2007 Jun 7;26(27):3972-9. doi: 10.1038/sj.onc.1210166. Epub 2006 Dec 18. Oncogene. 2007. PMID: 17173063 - Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
Pan R, Ruvolo VR, Wei J, Konopleva M, Reed JC, Pellecchia M, Andreeff M, Ruvolo PP. Pan R, et al. Blood. 2015 Jul 16;126(3):363-72. doi: 10.1182/blood-2014-10-604975. Epub 2015 Jun 4. Blood. 2015. PMID: 26045609 Free PMC article. - Targeting multiple arms of the apoptotic regulatory machinery.
Dai Y, Grant S. Dai Y, et al. Cancer Res. 2007 Apr 1;67(7):2908-11. doi: 10.1158/0008-5472.CAN-07-0082. Cancer Res. 2007. PMID: 17409392 Review.
Cited by
- MiRNA-16-1 Suppresses Mcl-1 and Bcl-2 and Sensitizes Chronic Lymphocytic Leukemia Cells to BH3 Mimetic ABT-199.
Ashofteh N, Mahbod ASA, Bayat M, Karami H. Ashofteh N, et al. Cell J. 2022 Aug 28;24(8):473-480. doi: 10.22074/cellj.2022.8101. Cell J. 2022. PMID: 36093807 Free PMC article. - MicroRNA-520d-3p suppresses melanoma cells proliferation by inhibiting the anti-silencing function 1B histone chaperone.
Shi X, Xu X, Shi N, Chen Y, Fu M. Shi X, et al. Bioengineered. 2021 Dec;12(2):10703-10715. doi: 10.1080/21655979.2021.2001914. Bioengineered. 2021. PMID: 34872448 Free PMC article. - B-cell lymphoma 2 family genes show a molecular pattern of spatiotemporal heterogeneity in gynaecologic and breast cancer.
Wang J, Li S, Lin S, Fu S, Qiu L, Ding K, Liang K, Du H. Wang J, et al. Cell Prolif. 2020 Jun;53(6):e12826. doi: 10.1111/cpr.12826. Epub 2020 May 17. Cell Prolif. 2020. PMID: 32419250 Free PMC article. - The miRNA and mRNA Signatures of Peripheral Blood Cells in Humans Infected with Trypanosoma brucei gambiense.
Lueong S, Leong S, Simo G, Camara M, Jamonneau V, Kabore J, Ilboudo H, Bucheton B, Hoheisel JD, Clayton C. Lueong S, et al. PLoS One. 2013 Jun 27;8(6):e67312. doi: 10.1371/journal.pone.0067312. Print 2013. PLoS One. 2013. PMID: 23826264 Free PMC article. - Epigenetically altered miR-193b targets cyclin D1 in prostate cancer.
Kaukoniemi KM, Rauhala HE, Scaravilli M, Latonen L, Annala M, Vessella RL, Nykter M, Tammela TL, Visakorpi T. Kaukoniemi KM, et al. Cancer Med. 2015 Sep;4(9):1417-25. doi: 10.1002/cam4.486. Epub 2015 Jul 1. Cancer Med. 2015. PMID: 26129688 Free PMC article.
References
- Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297. - PubMed
- Lewis B.P., Shih I.H., Jones-Rhoades M.W., Bartel D.P., Burge C.B. Prediction of mammalian microRNA targets. Cell. 2003;115:787–798. - PubMed
- Miranda K.C., Huynh T., Tay Y., Ang Y.S., Tam W.L., Thomson A.M., Lim B., Rigoutsos I. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell. 2006;126:1203–1217. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials